Anti-TNF agents in familial Mediterranean fever: Report of three cases and review of the literature

Modern Rheumatology

Volumn 21, Issue 6, 2011, Pages 684-690

  Ozgocmen, Salih ^a   Akgul, Ozgur ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Anti TNF; Biologics; Familial Mediterranean fever

Indexed keywords

ACEMETACIN; ADALIMUMAB; CANAKINUMAB; CITALOPRAM; COLCHICINE; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PETHIDINE; PREDNISOLONE; QUETIAPINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ADULT; AMYLOIDOSIS; ARTHRALGIA; ARTICLE; CASE REPORT; COMORBIDITY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMAN; LOW BACK PAIN; PRIORITY JOURNAL; RETREATMENT; SPONDYLITIS; TREATMENT DURATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855658573     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0463-2     Document Type: Article

References (48)

1. Grateau G, Duruoz MT. Autoinflammatory conditions: When to suspect? How to treat? Best Pract Res Clin Rheumatol. 2010;24:401-11.
2. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659-64. (Pubitemid 28098460)
3. Berkun Y, Ben-Chetrit E, Klar A. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever-are they more frequent? Semin Arthritis Rheum. 2007;36:316-21. (Pubitemid 46517633)
4. Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum. 2001;44:1416-9. (Pubitemid 32537542)
5. Younes M, Kahn MF, Meyer O. Hip involvement in patients with familial Mediterranean fever. A review of ten cases. Joint Bone Spine. 2002;69:560-5. (Pubitemid 36050357)
6. Incel NA, Saracoglu M, Erdem HR. Seronegative spondyloarthropathy of familial Mediterranean fever. Rheumatol Int. 2003;23:41-3. (Pubitemid 36207856)
7. Kaushik P, el-Sobkie NI, Shehab D, Malaviya AN. Familial Mediterranean fever with HLA B-27 positive ankylosing spondylitis in a young Armenian man. Clin Exp Rheumatol. 1999;17:387-8. (Pubitemid 29265693)
8. Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum. 1996;26:612-27. (Pubitemid 27024198)
9. Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: An update. Curr Drug Targets Inflamm Allergy. 2005;4:117-24. (Pubitemid 40584862)
10. Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol. 2004;10:134-7. (Pubitemid 38821988)
11. Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum. 2005;53:146-7. (Pubitemid 40216369)
12. Yuksel S, Yalcinkaya F, Acar B, Ozcakar ZB, Ozturk B, Ekim M. Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford). 2006;45:1307-8. (Pubitemid 44542076)
13. Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol. 2006;24:435-7. (Pubitemid 44363547)
14. Ozgocmen S, Ozcakar L, Ardicoglu O, Kocakoc E, Kaya A, Kiris A. Familial Mediterranean fever responds well to infliximab: Single case experience. Clin Rheumatol. 2006;25:83-7.
15. Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: Thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol. 2006;24:S99-103. (Pubitemid 44696888)
16. Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol. 2007;13:38-40. (Pubitemid 46213843)
17. Bodur H, Seckin U, Eser F, Ergul G, Seckin S. Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy. Rheumatol Int. 2008;29:107-10.
18. Kaya S, Kaptanoglu E, Elden H, Hizmetli S. Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept. Intern Med. 2010;49:619-22.
19. Nakamura A, Matsuda M, Tazawa K, Shimojima Y, Ikeda S. Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Intern Med. 2007;46:1247-9. (Pubitemid 47354446)
20. Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. Clin Rheumatol. 2010;29:209-10.
21. Alpay N, Sumnu A, Caliskan Y, Yazici H, Turkmen A, Gul A. Efficacy of anakinra treatment in a patient with colchicineresistant familial Mediterranean fever. Rheumatol Int. 2010.
22. Garcia-Gonzalez A, Weisman MH. The arthritis of familial Mediterranean fever. Semin Arthritis Rheum. 1992;22:139-50. (Pubitemid 23007018)
23. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287:1302.
24. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314:1001-5. (Pubitemid 16138694)
25. Ben-Chetrit E, Ozdogan H. Non-response to colchicine in FMF- definition, causes and suggested solutions. Clin Exp Rheumatol. 2008;26:S49-51.
26. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: Clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum. 2004;33:273-82. (Pubitemid 38280826)
27. Tufan A, Babaoglu MO, Akdogan A, et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol. 2007;34:1540-4. (Pubitemid 47067992)
28. Silva LC, Ortigosa LC, Benard G. Anti-TNF-αlpha agents in the treatment of immune-mediated inflammatory diseases: Mechanisms of action and pitfalls. Immunotherapy. 2010;2:817-33.
29. Baykal Y, Saglam K, Yilmaz MI, Taslipinar A, Akinci SB, Inal A. Serum sIL-2r, IL-6, IL-10 and TNF-αlpha level in familial Mediterranean fever patients. Clin Rheumatol. 2003;22:99-101. (Pubitemid 36748856)
30. Gang N, Drenth JP, Langevitz P, et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol. 1999;26:890-7. (Pubitemid 29195678)
31. Yilmaz E, Balci B, Kutlay S, et al. Analysis of the modifying effects of SAA1, SAA2 and TNF-αlpha gene polymorphisms on development of amyloidosis in FMF patients. Turk J Pediatr. 2003;45:198-202. (Pubitemid 37407353)
32. Celebi Kobak A, Kobak S, Kabasakal Y, Akarca US. Tumor necrosis factor-alpha gene promoter polymorphism in patients with familial Mediterranean fever. Clin Rheumatol. 2007;26:908-10. (Pubitemid 46951287)
33. Haddad JJ. The role of inflammatory cytokines and NF-kappaB/ MAPK signaling pathways in the evolution of familial Mediterranean fever: Current clinical perspectives and potential therapeutic approaches. Cell Immunol. 2009;260:6-13.
34. Papin S, Cazeneuve C, Duquesnoy P, Jeru I, Sahali D, Amselem S. The tumor necrosis factor alpha-dependent activation of the human mediterranean fever (MEFV) promoter is mediated by a synergistic interaction between C/EBP beta and NF kappaB p65. J Biol Chem. 2003;278:48839-47.
35. Ryan JG, Masters SL, Booty MG, et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin, the familial Mediterranean fever protein. Ann Rheum Dis. 2010;69:1383-8.
36. Kasifoglu T, Calisir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLAB27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol. 2009;28:41-6.
37. Cinar M, Dinc A, Simsek I, et al. The rate and significance of Mediterranean fever gene mutations in patients with ankylosing spondylitis: A three-month, longitudinal clinical study. Rheumatol Int. 2008;29:37-42.
38. Chae JJ,Wood G, RichardK, et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood. 2008;112:1794-803.
39. Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: New therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine. 2008;75:504-5.
40. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002;20:S1-13. (Pubitemid 35174747)
41. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr. 2008;167:695-6. (Pubitemid 351503491)
42. Gattringer R, Lagler H, Gattringer KB, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: Effective but risky. Eur J Clin Invest. 2007;37:912-4. (Pubitemid 350029205)
43. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis. 2007;66:1545-6. (Pubitemid 350032672)
44. Hennig S, Bayegan K, Uffmann M, Thalhammer F, Winkler S. Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review. Rheumatol Int. 2010.
45. Moser C, Pohl G, Haslinger I, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant. 2009;24:676-8.
46. Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: A case series and a review of the literature. Semin Arthritis Rheum. 2011.
47. Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis. 2011. doi:10.1136/ard.2010.146878.
48. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebocontrolled studies. Arthritis Rheum. 2008;58:2443-52.